

**AMENDMENTS TO THE CLAIMS**

**Listing of Claims:**

- 1-14. (Cancelled)
15. (Currently Amended) ~~The use~~ A method of manufacturing a pharmaceutical composition for the prevention and/or therapy of vasculitis, comprising mixing an [[of]] interleukin-6 (IL-6) antagonist with a pharmaceutically acceptable excipient for the manufacture of a preventive and/or therapeutic agent for vasculitis.
16. (Withdrawn-Currently Amended) ~~The use~~ A method of manufacturing a pharmaceutical composition for the prevention and/or therapy of vasculitis having resistance to steroids and/or immunosuppressants, comprising mixing an [[of]] interleukin-6 (IL-6) antagonist with a pharmaceutically acceptable excipient for the manufacture of a preventive and/or therapeutic agent for vasculitis having resistance to steroids and/or immunosuppressants.
17. (Currently Amended) The [[use]] method according to claim 15 wherein said vasculitis is polyarteritis nodosa.
18. (Withdrawn-Currently Amended) The [[use]] method according to claim 15 wherein said vasculitis is the aortitis syndrome.
19. (Withdrawn-Currently Amended) The [[use]] method according to claim 15 wherein said vasculitis is vasculitis associated with immunological abnormalities.
20. (Currently Amended) The [[use]] method according to claim 15 wherein said IL-6 antagonist is an antibody against IL-6 receptor.
21. (Currently Amended) The [[use]] method according to claim 20 wherein said antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.
22. (Currently Amended) The [[use]] method according to claim 20 wherein said antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

23. (Withdrawn-Currently Amended) The method according to claim 20 wherein said antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

24. (Currently Amended) The method according to claim 20 wherein said antibody against IL-6 receptor is a recombinant antibody.

25. (Currently Amended) The method according to claim 22 wherein said monoclonal antibody against human IL-6 receptor is PM-1 antibody.

26. (Withdrawn-Currently Amended) The method according to claim 23 wherein said monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

27. (Currently Amended) The method according to claim 20 wherein said antibody against IL-6 receptor is a chimeric antibody, a humanized antibody, or a human antibody.

28. (Currently Amended) The method according to claim 27 wherein said humanized antibody against IL-6 receptor is a humanized PM-1 antibody.

29. (Withdrawn) A method of preventing and/or treating vasculitis comprising administering an interleukin-6 (IL-6) antagonist to a subject in need thereof.

30. (Original) A method of preventing and/or treating vasculitis having resistance to steroids and/or immunosuppressants, comprising administering an interleukin-6 (IL-6) antagonist to a subject in need thereof.

31. (Previously Presented) The method according to claim 29 wherein said vasculitis is polyarteritis nodosa.

32. (Withdrawn) The method according to claim 29 wherein said vasculitis is the aortitis syndrome.

33. (Withdrawn) The method according to claim 29 wherein said vasculitis is vasculitis associated with immunological abnormalities.

34. (Previously Presented) The method according to claim 29 wherein said IL-6 antagonist is an antibody against IL-6 receptor.

35. (Original) The method according to claim 34 wherein said antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

36. (Original) The method according to claim 34 wherein said antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

37. (Withdrawn) The method according to claim 34 wherein said antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

38. (Previously Presented) The method according to claim 34 wherein said antibody against IL-6 receptor is a recombinant antibody.

39. (Original) The method according to claim 36 wherein said monoclonal antibody against human IL-6 receptor is PM-1 antibody.

40. (Withdrawn) The method according to claim 37 wherein said monoclonal antibody against mouse IL-6 receptor is MR1 antibody.

41. (Previously Presented) The method according to claim 34 wherein said antibody against IL-6 receptor is a chimeric antibody, humanized antibody, or a human antibody against IL-6 receptor.

42. (Original) The method according to claim 41 wherein said humanized antibody against IL-6 receptor is a humanized PM-1 antibody.